 |
|
|
|
|
|
|
|
 |
Results for 'Novartis' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Novartis
PharmaVitae Profile
|
January 2007 |
£3010 |
100 % |
Novartis
Pipeline Products Performance Potential
|
February 2008 |
£595 |
100 % |
Novartis AG -Therapeutic Competitors
|
February 2008 |
£175 |
97 % |
Novartis: PharmaVitae Profile
|
February 2007 |
£1060 |
97 % |
Novartis AG - SWOT Analysis
|
September 2007 |
£125 |
97 % |
Novartis IMS Company Profile
|
December 2006 |
£510 |
96 % |
Novartis AG -Deals & Alliances Report
|
February 2008 |
£300 |
96 % |
Novartis AG -Financial Company Report
|
February 2008 |
£175 |
96 % |
Novartis AG -Detailed Product Pipeline
|
February 2008 |
£375 |
96 % |
Novartis Partnering Guide 2008
|
July 2021 |
£195 |
96 % |
Spotlight Report Series: Deal Making Spotlight on Novartis
|
April 2006 |
£350 |
84 % |
Chinese Pharmaceutical Market Overview
Regulatory reform and the evolving healthcare market provide opportunities in china
|
November 2007 |
£3010 |
50 % |
Aliskiren: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
35 % |
OTC Healthcare Company Profile - Novartis AG
|
May 2006 |
£195 |
35 % |
Premium Company Profile Idenix Pharmaceuticals, Inc.
|
October 2007 |
£265 |
30 % |
Chemical and Pharmaceutical Industry in China, The
Chances and Threats for Foreign Companies
|
December 2004 |
£30.5 |
28.5 % |
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
|
July 2007 |
£7600 |
27.5 % |
Spotlight Report Series: Deal Making Spotlight on Pfizer
|
April 2006 |
£350 |
24 % |
Sgx Pharmaceuticals Inc
Premium Company Profile
|
December 2007 |
£265 |
24 % |
Spotlight Report Series: Deal Making Spotlight on Sanofi-Aventis
|
April 2006 |
£350 |
24 % |
Spotlight Report Series: Deal Making Spotlight on Johnson & Johnson
|
April 2006 |
£350 |
24 % |
Spotlight Report Series: Deal Making Spotlight on GlaxoSmithKline
|
April 2006 |
£350 |
24 % |
India Pharmaceuticals & Healthcare
|
September 2007 |
£360 |
23.5 % |
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market?
- Cancer
|
October 2007 |
£7600 |
23.5 % |
Pharmaceuticals in Poland
|
January 2008 |
£125 |
22.75 % |
OTC Pharmaceuticals in Asia-Pacific
|
December 2007 |
£125 |
22.4 % |
OTC Pharmaceuticals in Norway
|
January 2008 |
£125 |
22.4 % |
OTC Pharmaceuticals in Sweden
|
January 2008 |
£125 |
22.4 % |
Global OTC Pharmaceuticals
|
December 2007 |
£125 |
22.4 % |
OTC Pharmaceuticals in Japan
|
January 2008 |
£125 |
22.4 % |
Pharmaceuticals in Sweden
|
January 2008 |
£125 |
22.05 % |
Pharmaceuticals in Brazil
|
January 2008 |
£125 |
22.05 % |
OTC Pharmaceuticals in Denmark
|
January 2008 |
£125 |
22.05 % |
OTC Pharmaceuticals in Brazil
|
January 2008 |
£125 |
22.05 % |
Risk-Sharing in the Pharmaceutical Industry
The Case of Out-Licensing
|
January 2006 |
£50 |
22 % |
Pharmaceuticals in Asia-Pacific
|
December 2007 |
£125 |
21.7 % |
Biotechnology in the United Kingdom
|
September 2008 |
£180 |
21.7 % |
Pharmaceuticals in Hungary
|
January 2008 |
£125 |
21.7 % |
OTC Pharmaceuticals in Belgium
|
December 2007 |
£125 |
21.7 % |
Pharmaceuticals in the Czech Republic
|
January 2008 |
£125 |
21.7 % |
Pharmaceuticals in Singapore
|
December 2007 |
£125 |
21.7 % |
Valsartan: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
21.5 % |
Fluvastatin: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
21.5 % |
Letrozole: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
21 % |
Rivastigmine: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
21 % |
Zoledronic Acid: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
21 % |
Terbinafine: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
20.5 % |
Famciclovir: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
20.5 % |
Entacapone: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
20.5 % |
Deracoxib (vet): Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
20.5 % |
Cyclosporin (vet): Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
20 % |
Nateglinide: Pipeline™ Developer
Patent Report
|
Ongoing |
£1825 |
19.5 % |
Fluvastatin: Pipeline™ Developer
Patent Report
|
Ongoing |
£2460 |
19.5 % |
Letrozole: Pipeline™ Developer
Patent Report
|
Ongoing |
£1825 |
19.5 % |
Zoledronic Acid: Pipeline™ Developer
Patent Report
|
Ongoing |
£2120 |
19.5 % |
Rivastigmine: Pipeline™ Developer
Patent Report
|
Ongoing |
£1825 |
19.5 % |
Valsartan: Pipeline™ Developer
Patent Report
|
Ongoing |
£2460 |
19.5 % |
Entacapone: Pipeline™ Developer
Patent Report
|
Ongoing |
£1825 |
19 % |
Terbinafine: Pipeline™ Developer
Patent Report
|
Ongoing |
£1825 |
19 % |
Octreotide: Pipeline™ Developer
Patent Report
|
Ongoing |
£2120 |
19 % |
Famciclovir: Pipeline™ Developer
Patent Report
|
Ongoing |
£2120 |
19 % |
Watson
Pharmavitae Generics Profile
|
September 2007 |
£2005 |
18 % |
Leukemia - A Therapeutic & Competitive Insight
|
October 2006 |
£1660 |
18 % |
Generic Option; The
|
July 2006 |
£440 |
17.5 % |
Oncology Market Forecast to 2013
|
July 2008 |
£10625 |
17.5 % |
OTC Healthcare in Switzerland to 2010
|
September 2007 |
£265 |
17 % |
OTC Healthcare in Israel to 2010
|
September 2007 |
£265 |
17 % |
OTC Healthcare in Sweden to 2010
|
September 2007 |
£265 |
17 % |
OTC Healthcare in Brazil to 2010
|
September 2007 |
£265 |
17 % |
Prostate and Breast Cancer- New Treatments & Developmental Progress
|
March 2007 |
£2510 |
17 % |
Report on China's Anti-fungal Drug Industry
|
December 2006 |
£195 |
16.5 % |
Dipeptidyl peptidase IV (DPP-IV) Inhibitors
Competitor Analysis
|
November 2008 |
£105 |
16.5 % |
Failures in Functional Foods
10 Key Case Studies & 10 Key Lessons
|
February 2007 |
£145 |
16.1 % |
Breast Cancer
The Latest R&D Trends
|
February 2007 |
£1660 |
16 % |
Hematological Cancers - A Therapeutic & Competitive Insight
|
October 2006 |
£2510 |
16 % |
Defending Brand Revenue
Pharmaceutical Lifecycle Management Planning
|
July 2005 |
£2530 |
16 % |
Powering Discovery through Target Evaluation
Moving Beyond the Validation Paradigm
|
August 2005 |
£1950 |
15.75 % |
Global Biotechnology Industry 2006
|
June 2006 |
£550 |
15.75 % |
Monoclonal Antibodies in Asthma
The choice between life and breath?
|
February 2006 |
£1095 |
15.5 % |
Premium Company Profile Barrier Therapeutics
|
October 2007 |
£265 |
15.5 % |
Urinary Incontinence - Lifecycle Management Strategies Retain Mid-Term Market Growth
Pipeline And Commercial Insight
|
December 2007 |
£7600 |
15.4 % |
Beyond the Blockbuster Drug
Strategies for nichebuster drugs, targeted therapies and personalized medicine.
|
February 2005 |
£1495 |
15.4 % |
Financial Markets Research: ASCO Review Part II
A summary of highlights presented at the ASCO 2006 Annual Meeting
|
August 2006 |
£2195 |
15.05 % |
Crisis Management And Corporate Reputation
Counter-Generics Strategy, Tactics and Execution
|
November 2007 |
£4560 |
15 % |
Gastrointestinal Disorders Market Intelligence to 2012
|
May 2007 |
£1499 |
15 % |
MorphoSys Ag
Premium Company Profile
|
April 2008 |
£265 |
15 % |
Combating Generics 2008
Counter-Generics Strategy, Tactics and Execution
|
December 2007 |
£5015 |
15 % |
Corporate Security
Protecting Productivity
|
December 2007 |
£4560 |
15 % |
Wound Treatments in Spain
|
July 2006 |
£450 |
14.7 % |
New Drug Futures: Respiratory Chapter
|
May 2006 |
£695 |
14.7 % |
Wound Treatments in Germany
|
July 2008 |
£450 |
14.7 % |
Educating the Market: Creating Value Through Support of Continuing Medical Education
|
March 2008 |
£2260 |
14.5 % |
Xoma Limited
Premium Company Profile
|
December 2007 |
£265 |
14.5 % |
Digestive Remedies in Germany
|
July 2008 |
£450 |
14.35 % |
Analgesics in Germany
|
July 2008 |
£450 |
14.35 % |
Medicated Skin Care in Germany
|
July 2008 |
£450 |
14.35 % |
Pharmaceutical Licensing Strategies
Best practices in deal-making, valuations and strategic management
|
June 2006 |
£1495 |
14.35 % |
Analgesics in Spain
|
July 2006 |
£450 |
14.35 % |
Eye Care in Spain
|
July 2006 |
£450 |
14.35 % |
Slovenia Pharmaceuticals and Healthcare Report Q4 2008
|
October 2008 |
£425 |
14.35 % |
Eye Care in Germany
|
July 2008 |
£450 |
14.35 % |
AMD Market Outlook to 2012
|
March 2007 |
£1299 |
14.35 % |
NRT Smoking Cessation Aids in Germany
|
July 2008 |
£450 |
14.35 % |
OTC Pharmaceuticals
Global Industry Guide
|
February 2008 |
£790 |
14 % |
Digestive Remedies in Spain
|
July 2006 |
£450 |
14 % |
Eye Care in United States
|
May 2006 |
£450 |
14 % |
Vitamins And Dietary Supplements in Germany
|
July 2008 |
£450 |
14 % |
Partneringreview 2006
|
February 2006 |
£2195 |
14 % |
NRT Smoking Cessation Aids in Spain
|
July 2006 |
£450 |
14 % |
Pipeline And Commercial Insight: Parkinson's Disease
Market To Grow As First Round Of Lifecycle Management Strategies Succeed
|
September 2007 |
£7600 |
14 % |
Vitamins and Dietary Supplements in Spain
|
July 2006 |
£450 |
14 % |
Global Pharmaceuticals - Yearly Update 2006
|
July 2007 |
£600 |
14 % |
NRT Smoking Cessation Aids in United States
|
May 2006 |
£450 |
13.65 % |
Merger & Acquisition Agreements in Biopharma
|
February 2001 |
£1195 |
13.65 % |
Cough, Cold And Allergy (Hay Fever) Remedies in Germany
|
July 2008 |
£450 |
13.65 % |
Monoclonal Antibodies Report Part II
Companies - Holding Mabs In Portfolio Promises Protection Against The Looming 2011-12 Patent Cliff
|
September 2007 |
£3800 |
13.65 % |
Digestive Remedies in United States
|
May 2006 |
£450 |
13.65 % |
Medicated Skin Care in the Czech Republic
|
November 2007 |
£450 |
13.65 % |
'Big Pharma' Turns to Biologics for Growth to 2010
Financial and strategic segmentation of the 'Big Pharma' sector by drug technology
|
May 2006 |
£4000 |
13.65 % |
Vitamins And Dietary Supplements in United States
|
May 2006 |
£450 |
13.65 % |
NBTY Inc - OTC Healthcare - World
|
January 2008 |
£195 |
13.65 % |
Medicated Skin Care in Spain
|
July 2006 |
£450 |
13.65 % |
Medicated Skincare in Spain
|
November 2005 |
£450 |
13.65 % |
Partneringreview 2006 – Financings
Volume 3
|
February 2006 |
£1395 |
13.5 % |
Partneringreview 2006 – Deal Type
Volume 5
|
February 2006 |
£1395 |
13.5 % |
Partneringreview 2006 – Therapy Area
Volume 2
|
February 2006 |
£1395 |
13.5 % |
Partneringreview 2006 - Company Deal Index
Volume 1
|
February 2006 |
£1395 |
13.5 % |
Partneringreview 2006 – Stage of Development
Volume 4
|
February 2006 |
£1395 |
13.5 % |
Partneringreview 2006 – Industry Sector
Volume 6
|
February 2006 |
£1395 |
13.5 % |
Stakeholder Opinions: Respiratory Syncytial Virus (RSV)
A market yet to reach its full potential
|
December 2006 |
£2005 |
13.5 % |
Stakeholder Opinions Respiratory Syncytial Virus (RSV)
A market yet to reach its full potential
|
January 2007 |
£2005 |
13.5 % |
Infinity Pharmaceuticals Inc
Premium Company Profile
|
December 2007 |
£265 |
13.5 % |
U.S. Sales Communications Excellence: Resources, Structure and Processes to Optimize Pharmaceutical Sales Communications
|
April 2008 |
£940 |
13.5 % |
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape
|
August 2008 |
£3800 |
13.3 % |
Cough, Cold and Allergy (Hay Fever) Remedies in Vietnam
|
January 2008 |
£450 |
13.3 % |
Digestive Remedies in China
|
September 2007 |
£450 |
13.3 % |
Digestive Remedies in Canada
|
August 2007 |
£450 |
13.3 % |
Digestive Remedies in Belgium
|
January 2008 |
£450 |
13.3 % |
Digestive Remedies in Australia
|
November 2007 |
£450 |
13.3 % |
The Gastrointestinal Market Outlook to 2010
|
January 2006 |
£1495 |
13.3 % |
Model Animal Systems
Emerging Applications and Commercial Opportunities in Drug Discovery and Development
|
June 2004 |
£1946 |
13.3 % |
Medicated Skin Care in Vietnam
|
January 2008 |
£450 |
13.3 % |
Cough, Cold and Allergy (Hay Fever) Remedies in Spain
|
July 2006 |
£450 |
13.3 % |
Medicated Skin Care in Venezuela
|
February 2008 |
£450 |
13.3 % |
Global Biotechnology -Yearly Update 2006
|
July 2007 |
£600 |
13.3 % |
Medicated Skin Care in United States
|
May 2006 |
£450 |
13.3 % |
Medicated Skin Care in the United Kingdom
|
July 2007 |
£450 |
13.3 % |
Pipeline Insight: Bipolar Disorder
New treatments for bipolar depression set to drive near-term growth
|
September 2006 |
£6495 |
13 % |
Stakeholder Opinions: Irritable Bowel Syndrome
Potentially profitable market is open for the taking
|
June 2007 |
£1900 |
13 % |
Maximizing Your Brand Value
|
August 2007 |
£4560 |
13 % |
Maintaining a Competitive Edge in Pharmaceutical Public Affairs: Benchmarking the Resources Required to Serve the U.S. Market
|
February 2008 |
£2190 |
13 % |
Stakeholder Opinions: Irritable Bowel Syndrome
Potentially profitable market is open for the taking
|
June 2007 |
£1900 |
13 % |
Japanese Pharmaceutical Market, 2006-2011
|
January 2006 |
£1499 |
13 % |
Pipeline Insight: Osteoarthritis
The Wait for a DMOAD Continues
|
November 2006 |
£6000 |
13 % |
Digestive Remedies in Brazil
|
August 2007 |
£450 |
12.95 % |
Pipeline Insight Asthma/COPD/Allergic Rhinitis
As Patents Expire, Novel Combinations Inspire
|
April 2005 |
£6000 |
12.95 % |
Merck KGaA - OTC Healthcare - World
|
January 2008 |
£195 |
12.95 % |
Switzerland Pharmaceuticals & Healthcare
|
September 2006 |
£395 |
12.95 % |
Cough, Cold And Allergy (Hay Fever) Remedies in United States
|
May 2006 |
£450 |
12.95 % |
Wound Treatment in Mexico
|
December 2005 |
£450 |
12.95 % |
Top 10 Generic Pharmaceutical Companies, The
Positioning, Performance and SWOT Analyses
|
July 2008 |
£1995 |
12.95 % |
Wound Treatments in the United Kingdom
|
August 2006 |
£450 |
12.95 % |
Animal Pharm's Top Tier Companies
2007 edition
|
January 2007 |
£895 |
12.95 % |
Wound Treatment in the United Kingdom
|
December 2005 |
£450 |
12.95 % |
Smoking Cessation Aids in the United Kingdom
|
December 2005 |
£450 |
12.95 % |
Eye Care in the United Kingdom
|
August 2006 |
£450 |
12.95 % |
Analgesics in the UK
|
March 2006 |
£450 |
12.95 % |
Medicated Skincare in the United Kingdom
|
December 2005 |
£450 |
12.6 % |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
|
July 2007 |
£1545 |
12.6 % |
Eye Care in Norway
|
May 2006 |
£450 |
12.6 % |
Medicated Skin Care in the UK
|
March 2006 |
£450 |
12.6 % |
Wound Treatment in Switzerland
|
December 2005 |
£450 |
12.6 % |
Smoking Cessation Aids in Switzerland
|
December 2005 |
£450 |
12.6 % |
Eye Care in Mexico
|
February 2008 |
£450 |
12.6 % |
Digestive Remedies in the UK
|
March 2006 |
£450 |
12.6 % |
UK Pharmaceutical Products
Market research report
|
September 2001 |
£600 |
12.6 % |
Digestive Remedies in Ireland
|
August 2007 |
£450 |
12.6 % |
Digestive Remedies in Argentina
|
August 2007 |
£450 |
12.6 % |
Analgesics in Mexico
|
February 2008 |
£450 |
12.6 % |
Vitamins And Dietary Supplements in the UK
|
March 2006 |
£450 |
12.6 % |
Smoking Cessation Aids in Mexico
|
December 2005 |
£450 |
12.6 % |
UK Pharmaceutical Products Market Development Report
|
September 2001 |
£600 |
12.6 % |
CNS Market Outlook to 2011, The
|
November 2006 |
£1495 |
12.6 % |
Wound Treatments in Mexico
|
September 2006 |
£450 |
12.6 % |
The CNS Market Outlook to 2011
|
November 2006 |
£1495 |
12.6 % |
Analgesics in the United Kingdom
|
August 2006 |
£450 |
12.6 % |
Wound Treatments in Norway
|
May 2006 |
£450 |
12.6 % |
Rewarding & Recognizing Top-Performing Sales People
|
March 2008 |
£2260 |
12.5 % |
Diabetes Drug Discoveries
What the Future Holds
|
January 2007 |
£1495 |
12.5 % |
Digestive Remedies in New Zealand
|
January 2008 |
£450 |
12.25 % |
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
|
June 2006 |
£1495 |
12.25 % |
Digestive Remedies in the United Kingdom
|
August 2006 |
£450 |
12.25 % |
Digestive Remedies in Malaysia
|
December 2007 |
£450 |
12.25 % |
Pharmaceutical Strategic Alliances
Maximizing returns from collaborative development and commercialization
|
September 2006 |
£1495 |
12.25 % |
Health Benefit Platforms & Strategies in Breakfast Cereals
17 Key Case Studies
|
January 2007 |
£145 |
12.25 % |
NRT Smoking Cessation Aids in the United Kingdom
|
August 2006 |
£450 |
12.25 % |
The Future of Monoclonal Antibodies Therapeutics
Innovation in antibody engineering, key growth strategies and forecasts to 2011
|
July 2006 |
£1495 |
12.25 % |
Digestive Remedies in Japan
|
September 2007 |
£450 |
12.25 % |
Vitamins and Dietary Supplements in the United Kingdom
|
August 2006 |
£450 |
12.25 % |
Medicated Skin Care in the United Kingdom
|
August 2006 |
£450 |
12.25 % |
Smoking Cessation Aids in Germany
|
November 2005 |
£450 |
12.25 % |
The Cancer Market Outlook to 2010
|
January 2005 |
£1495 |
12.25 % |
Pharmaceutical Regulatory Affairs in The Eu & US
|
January 2006 |
£1095 |
12 % |
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
|
October 2006 |
£1660 |
12 % |
Consolidation in the Generic Pharmaceutical Industry
An evolving landscape
|
October 2007 |
£1250 |
12 % |
Vitamins and Dietary Supplements in Mexico
|
September 2006 |
£450 |
11.9 % |
Digestive Remedies in Norway
|
October 2007 |
£450 |
11.9 % |
Digestive Remedies in Mexico
|
February 2008 |
£450 |
11.9 % |
Future Growth Opportunities in Generics
The impact of consolidation on market and competitive dynamics
|
November 2006 |
£1495 |
11.9 % |
Cough, Cold And Allergy (Hay Fever) Remedies in the UK
|
March 2006 |
£450 |
11.9 % |
Medicated Skincare in Switzerland
|
December 2005 |
£450 |
11.9 % |
Digestive Remedies in Norway
|
May 2006 |
£450 |
11.9 % |
Eye Care in Denmark
|
December 2007 |
£450 |
11.9 % |
Digestive Remedies in Mexico
|
February 2008 |
£450 |
11.9 % |
NRT Smoking Cessation Aids in Mexico
|
February 2008 |
£450 |
11.9 % |
NRT Smoking Cessation Aids in Norway
|
May 2006 |
£450 |
11.9 % |
European Animal Health Markets & Opportunities
|
January 2007 |
£895 |
11.9 % |
The Cancer Market Outlook to 2011
|
October 2006 |
£1495 |
11.9 % |
Cough, Cold and Allergy (Hayfever) Remedies in the United Kingdom
|
December 2005 |
£450 |
11.9 % |
Medicated Skincare in Mexico
|
December 2005 |
£450 |
11.9 % |
The Cardiovascular Market Outlook to 2011
|
January 2007 |
£1495 |
11.9 % |
|
|
